natgillin/translations-raw huggingface dataset:
Thus, this embodiment relates to compounds of the invention having a binding affinity for the serotonin transporter which is at least 5, preferably at least 10 or even more preferred at least 20 or 30 times higher than the binding affinity for the dopamine transporter, preferably as measured by the methods described in Example 9—Transporter binding assay. 
Na taj se način ovaj oblik odnosi na spojeve izuma koji imaju afinitet vezanja za transporter serotonina koji je, najmanje 5, po mogućnosti najmanje 10 ili čak više, 20 ili 30 puta viši od afiniteta vezanja za dopamin transporter, po mogućnosti mjereno metodama opisanim u primjeru 9 test vezanja transportera.
The method of claim 21, wherein the compound is A method of treating inflammation that is associated with Duchenne's muscular dystrophy comprising administering to a patient in need thereof an effective amount of a compound of Formula I: 
11. Spoj, naznačen time što je namijenjen upotrebi u liječenju upale povezane s metaboličkim poremećajem, upalnom bolesti crijeva, neurodegenerativnim poremećajem ili poremećajem propadanja mišića, gdje je spoj spoj formule I:
In some embodiments, the cancer is not a solid tumor (i.e ., other than a solid tumor). In some examples, the cancer is a plasmacytoma. In some examples, the cancer is multiple myeloma, renal cell carcinoma, prostate cancer, lung cancer, melanoma, brain cancer (e.g ., glioblastoma), ovarian cancer, or breast cancer. 
Pripravak za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 12, naznačen time što je rak odabran iz skupine koju čine multipli mijelom, rak gušterače, karcinom bubrežnih stanica, rak prostate, rak pluća, melanom, rak mozga, rak jajnika, limfom, limfoidna neoplazma, mijelom, leukemija, neuroendokrini rak, raka štitnjače, mezoteliom, plazmocitom i sarkom.
Aclidinium or any of its steroisomers or mixture of stereoisomers, or a pharmaceutically acceptable salt or solvate thereof, for use improving the quality of sleep in respiratory patients. 
PATENTNI ZAHTJEVI m» Aklidinij ili bilo koji od njegovih steroizomera ili smjesa stereoizomera ili njegova farmaceutski prihvatljiva sol ili solvat za primjenu u poboljšanju kvalitete sna kod respiratornih bolesnika.
The kit of claim 21, comprising the nucleic acid encoding the chimeric Cas9 protein. 
polipeptid Cas9 ili nukleinska kiselina koja obuhvaća nukleotidnu sekvencu koja kodira polipeptid Cas9; i
0.04 g of roflumilast is added, and the mixture is stirred until a clear solution is obtained. 
Doda se 0.04 g roflumilasta i smjesa se miješa do dobivanja bistre otopine.
represents phenyl, which is unsubstituted, mono- or di-substituted, wherein the substituents are independently selected from the group consisting of halogen, (C1-C4)alkyl (especially methyl), (C1-C4)alkoxy (especially methoxy), trifluoromethyl, trifluoromethoxy, and dimethylamino. 
R' predstavlja fenil, koji je nesupstituiran, mono- ili di-supstituiran, pri čemu su supstituenti neovisno odabrani iz skupine koju čine halogen, (C1-Cy)alkil, (C;-Cy)alkoksi, trifluorometil, trifluorometoksi i dimetilamino; ili sol takvoga spoja.
A chemical conversion, such as acrylation, is furthermore normally accompanied with an increase in molecular weight and polarity which both increases the viscosity. 
Osim toga, kemijska pretvorba, kao što je akrilacija, popraćena je s porastom molekulske mase i polarnosti, pri čemu to dvoje doprinosi porastu viskoznosti.
the compound of (1) wherein W is a ring system of formula: wherein: 
Kompozicija bilo kojeg patentnog zahtjeva 1 do 9, gdje (1) je spoj formule:
The invention has the further object of providing a wireless remote control system which can be easily installed on existing boats without substantial modification of such boats. 
Izum ima daljnji cilj omogućiti bežični daljinski upravljački sustav koji se može lako ugraditi na postojeća plovila bez bitnih izmjena na takvim plovilima.
TEGYEYDGFDY and wherein the light chain comprises the sequences 
TEGYEYDGFDY i pri čemu laki lanac sadrži sekvence SEQ ID NO:4
The vitamins that can be added to the basic composition comprise: vitamin C, B, A, K and E. Further, trace elements such as selenium, iron and zinc can be added. 
Vitamini koji se mogu dodati osnovnoj sastavini su: Vitamin C, B, A, K 1 E. Mogu se, nadalje, dodati i elementi u tragovima, poput selena, željeza 1 cinka.
Garment, according to claim 1 characterized in that it is a pair of stretchy denim fabric trousers. A manufacturing method for a garment, comprising the step of: 
Odjevni predmet, u skladu s patentnim zahtjevom 1, naznačen time, da je to par hlača od elastične traper tkanine.
In another more particular embodiment of the invention there is provided a polynucleotide encoding a therapeutic antibody light chain, which polynucleotide comprises the sequence set forth in SEQ ID No:41 or 43. 
13. Polinukleotid koji kodira laki lanac terapijskog protutijela, naznačen time što navedeni polinukleotid ima slijed iznijet u SEQ ID No:41 ili 43.
The method of any one of claims 1 to 3, 6 to 7, 10 to 11 and 14, wherein the sample is selected from the group consisting of blood serum, blood plasma, whole blood and stool. 
Postupak sukladno bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, da je uzorak odabran iz skupine koja se sastoji od krvnog seruma, krvne plazme, pune krvi i stolice
A combined product comprising the antitumor agent according to any of [10] to [13] and a cancer chemotherapeutic agent. 
Kombinirani proizvod, naznačen time, da obuhvaća antitumorsko sredstvo za uporabu prema bilo kojem od zahtjeva 9 do 12 i jedno kemoterapeutsko sredstvo protiv raka.
a first illumination lamp capable of radiating ultraviolet rays; 
prvu rasvjetnu svjetiljku (15) koja može zračiti ultraljubičaste zrake;
encoding Physical Layer Pipe, PLP, data for carrying at least one service and Layer 1, L1, signaling data for signaling the PLP data; 
kodiranje podatka cijevi fizičke razine, PLP, za prijenos najmanje jednog servisa;
The method for the preparation of the agomelatine hydrochloride hydrate according to claim 4, wherein said aqueous HCl solution is added dropwise. 
Postupak za pripremu agomelatina hidroklorid hidrata u skladu s patentnim zahtjevom 4, naznačen time, da se vodena otopina HCI dodaje kap po kap.
m)—Milling of strips as far as a second road marking in the first traffic lane; 
glodanje brušenih traka (56a-56f) do druge oznake ceste (FBM2) prve prometne trake (FSt1);
the human Vk3-20/Jk sequence is operably linked to a mouse Ck region sequence; 
(a) humana sekvenca VK3-20/Jx je operativno povezana sa sekvencom mišje regije Cx;
opening the switching element and separating the auxiliary branch from the main branch by the switching element; 
u koraku f) prekidački element (11) se otvara, a pomoćna grana (9) se odvaja od glavne grane (8) prekidačkim elementom (11);
contacting a G protein-coupled receptor with an optionally labeled known ligand to the receptor in the presence or absence of a test compound, wherein the G protein-coupled receptor comprises an amino acid sequence selected from the group consisting of 
(a) stavljanje u kontakt G protein-kupiranog receptora sa po izboru označenim poznatim ligandom za receptor u prisutnosti ili odsutnosti test spoja, pri čemu navedeni G protein kupirani receptor obuhvaća aminokiselinsku sekvencu izabranu iz skupine koju čine:
The yield of micropellets remaining on Sieves Nos. 40 to 80 was determined to be 58.0%, based on the total amount of ingredients. 
Određeno je da je prinos mikropeleta koje su zaostale na sitima broj 40 1 80 bio 58.0 %, na osnovi ukupne količine sastojaka.
Rupp H., Zarain-Herzberg A., Maisch B. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure//Herz, 2002-Vol. 
275-279.; Rupp H., Zarain-Herzberg A., Maisch B., Use of partial fatty acid oxidation inhibitors for mctabolic therapy of angina pectoris and hcartfailurc (Primjena inhibitora djelomične oksidacije masnih kiselina za metaboličku terapiju angine pektoris i otkazivanja srca)//Herz, 2002, sv.
and R9 independently are selected from the group consisting of OH, acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl; wherein each acyl, alkenyl, alkoxyl, alkyl, alkylamino, aryl, cycloalkyl, cycloalkylalkyl, heterocyclyl, and heterocyclylalkyl may be substituted with one or more radicals independently selected from the group consisting of halogen, N, O, —S—, —CN, —N3, nitro, oxo, acyl, alkyl, alkoxyl, alkylamino, alkenyl, aryl, (hetero-)cycloalkyl, and (hetero-)cyclyl; 
Ris je izabran iz grupe koju čine (Â«C=O)ORis, -OR:s, alkil 1 aril, pri čemu svaki alkil 1 aril mogu biti supstituirani; 1 Ris je izabran iz grupe koju čine H, acil, alkenil, alkoksil, OH, NH,, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil, gde svaki acil, alkenil, alkoksil, alkil, alkilamino, aril, alkilaril, cikloalkil, cikloalkilalkil, heteroaril, heterociklil 1 heterociklilalkil može biti supstituiran; i njegovi enantiomeri, diastereomeri, tautomeri, farmaceutski prihvatljive soli, hidrati, solvati i kompleksi.
A method for therapeutically increasing the diameter of an artery or vein in a human subject in need thereof, the method comprising: locally administering to the wall of the artery or vein in the human subject the pharmaceutical composition of any one of embodiments 460 to 464 in a dose sufficient to increase the diameter of the artery or vein. 
(iv) farmaceutski sastav je primijenjen na zidu krvnog suda pomoću katetera za isporuku lijeka; (b) terapijskog povećanja promjera arterije ili vene kod ljudskog subjekta kojem je to potrebno lokalno primjenjujući farmaceutski sastav na zid arterije ili vene kod ljudskog subjekta;
In one embodiment of the invention there is provided a process in which the heated liquid is transferred to a buffer tank prior to delivery to the radiator element. 
Postupak sukladno Zahtjevu 6 koji sadrži korak prijenosa zagrijane tekućine u sabirni spremnik (79), prije isporuke u element za zagrijavanje (15).
The particularly preferred derivatives or prodrugs are those that increase the bioavailability of compounds of the present invention when such compounds are administered to a patient (for example, allowing that an administered compound of oral form more quickly is absorbed in blood) or those that increase the liberation of the corresponding compound to a biological compartment (for example, the brain or the lymphatic system). 
Posebnu prednost imaju oni derivati koji povećavaju biološku raspoloživost spojeva predloženog izuma kad se takvi spojevi dadu pacijentu (koji omogućuju, na primjer, da se spoj primjenjen u oralnom obliku brže apsorbira u krvi) ili oni koji povećavaju oslobađanje odgovarajućeg spoja u biološkom području (na primjer, mozak ili limfni sistem).
The method of claim 1, wherein the therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof is provided at least one of sequentially or concomitantly, with another pharmaceutical agent in a newly diagnosed hematologic malignant proliferative disorder patient, to maintain remission of an existing patient, or a relapsed/refractory hematologic malignant proliferative disorder patient. 
Pripravak namijenjen uporabi u skladu s patentnim zahtjevom 1, pri čemu je terapeutski djelotvorna količina crenolaniba ili njegove farmaceutski prihvatljive soli osigurana barem jednom slijedno ili istodobno s drugim farmaceutskim agensom subjektu s novodijagnosticiranom akutnom mijeloičnom leukemijom (AML), za održavanje remisije kod subjekta ili subjektu s relapsiranom ili akutnom mijeloičnom leukemijom (AML).
The method of claim 10, further comprising: BCH encoding PLP data to generate an error protected data; 
BCH kodiranje podataka cijevi fizičke razine, naznačenih kao PLP podaci, zbog stvaranja podataka zaštićenih od pogreške;
The process according to any one of claims 8 to 12, further comprising reacting the compound of Formula VIIa with a compound of Formula IVa: under Suzuki coupling conditions to form a compound of Formula I: wherein the Suzuki coupling conditions comprise heating a reaction mixture comprising the compound of Formula VIIa, the compound of Formula IVa, a Suzuki coupling catalyst, a base and a second solvent component. 
Postupak prema zahtjevu 1, naznačen time što Suzukijevi uvjeti spajanja obuhvaćaju zagrijavanje reakcijske smjese koja se sastoji od spoja Formule IIIa, spoja Formule IVa, katalizatora Suzukijevog spajanja, baze i komponente otapala.
The method of claim 1, further comprising: generating a signal by the at least one controller that stops the cooking of the contents of the respective oven of the plurality of ovens when a defined cooking time is reached for a set of temperatures at which the respective oven was operated during at least part of a transit of the vehicle. 
Prenosivi sustav za kuhanje i dostavu prema zahtjevu 1, naznačen time, da najmanje jedna upravljačka jedinica (102, 118) zaustavlja kuhanje sadržaja u štednjaku (210), kada se postigne zadano vrijeme kuhanja za postavljene temperature na kojima je određeni štednjak radio za vrijeme barem dijela putovanja vozila (240), na temelju dinamički ažuriranog predviđenog vremena putovanja do dostavnog odredišta (304) za sadržine određenog štednjaka.
After concentration using a rotary evaporator, the oil (140 g, 90% pure by HPLC analysis) was not further purified but instead was carried forward as an impure diastereomeric mixture. 
Posije koncentriranja primjenom rotacijskog isparivača, ulje (140 g, 90% čistoće preko HPLC analize) nije dalje prečišćavano, već je umjesto toga dalje korišteno kao nečista diastereomerna smjesa.
ATR number of individual tests 
Broj međunarodne prijave:
The reaction was stirred overnight for 18 hr at 20°C. The reaction was stirred overnight for 18 hr at 20°C. HPLC analysis revealed a new peak which by LC/MS correspond to the mass of the expected O-methylglucoside. 
Reakcija je mješana preko noći 18 sati na 20%C. HPLC analiza je otkrila novi maksimum koji prema LC/MS odgovara masi očekivanog O-metilglukozida.
malt, malted barley, syrup. 
sladom, sladnim ječmom, sirupom.
The antibody according to claim 1, wherein the stabilized soluble a-synuclein oligomer comprises a stabilized soluble a-synuclein protofibril. 
Lijek za uporabu prema zahtjevu 1, pri čemu stabilizirani topivi oligomer a-sinukleina sadrži stabilizirani topivi protofibril a-sinukleina.
A developer supply container according to any one of Claims 1 - 21, wherein said drive converting portion (2d, 3b) converts the rotational force such that said developer accommodating chamber (2k) reciprocates with said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-21, naznačen time što navedeni dio za pretvorbu pogona (2d, 3b) pretvara silu vrtnje tako da navedena komora za držanje razvijača (2k) mijenja djelovanje s navedenim crpnim dijelom (2b).
fermentation of a part of the solid fraction and/or a part of the liquid fraction by an alcohol producing microorganism to produce alcohol, propagation of the alcohol producing microorganism by fermentation of a part of the liquid fraction and/or a part of the solid fraction, 
razmnožavanje mikroorganizma koji proizvode alkohol fermentacijom tekuće frakcije i fermentacijom tekuće frakcije mikroorganizmom koji stvara alkohol radi proizvodnje alkohola, pri čemu mikroorganizam koji proizvodi alkohol može fermentirati barem C5 šećer i barem C6 šećer,
A process for the preparation of vitamin K2 (MK - 7) comprising the culture of Bacillus subtilis mutant strain GN13/72 - DSM 17766 deposited on December O5, 2005 at the DSMZ. 
PATENTNI ZAHTJEVI 1. Postupak priprave vitamina K2 (MK - 7), naznačen time da obuhvaća mutanta kulture Bacillus subtilis soja GN13/72 - DSM 17766 položenog 5. prosinca 2005. u DSMZ.
The method according to claim 1, wherein reaction (N-reac) is done in a solvent (N-solv); solvent (N-solv) is selected from the group consisting of water, tert-butanol, isopropanol, acetonitrile, propionitrile, THF, methyl-THF, NMP, dioxane, 1,2-dimethoxyethane, dichloromethane, 1,2-dichloroethane, chloroform, toluene, benzene, chlorobenzene, hexane, cyclohexane, ethyl acetate, acetic acid, formic acid, trifluoroacetic acid and mixtures thereof. 
Postupak prema jednom ili više zahtjeva 1 do 10, naznačen time da se reakcija (N-reak.) provodi u otapalu (Notap.); otapalo (N-otap.) bude odabrano iz skupine koja se sastoji iz vode, terc-butanola, izopropanola, acetonitrila, propionitrila, THF, metil-THF, NMP, dioksana, 1,2-dimetoksietana, diklormetana, 1,2-dikloretana, kloroforma, toluola, benzola, klorbenzola, heksana, cikloheksana, etilnog estera octene kiseline, octene kiseline, mravlje kiseline, trifluoroctene kiseline i njihovih mješavina.
Apparatus according to claim 6 wherein the flow rate is between about 2,500 m3/hr (cubic meters per hour) and 3,500 m3/hr per 3,000 m3 of greenhouse volume. 
Uređaj prema zahtjevu 6, pri čemu je protok između oko 2.500 m3/h (kubnih metara po satu) 1 3.500 m3/h po zapremini staklenika od 3.000 m3.
A glassy lozenge for buccal drug delivery comprising an active agent selected from an anti-emetic agent, an agent for migraine treatment, and an analgesic agent, a non-crystalline matrix and a phosphate buffer, wherein the matrix comprises (i) a gum, and (ii) a non-crystallising sugar or non-crystallising sugar alcohol and wherein the matrix comprises, by weight, from 40-90% of gum component (i), and from 60-10% of the non-crystallising sugar or non-crystallising sugar alcohol component (ii). 
Staklasta tableta-pastila za bukalnu primjenu lijeka, naznačena time što sadrži aktivno sredstvo, matriks i fosfatni pufer, pri čemu matriks sadrži (i) gumu i (1i) ne-kristalizirajući šećer ili ne-kristalizirajući šećerni alkohol, pri čemu tableta sadrži manje od 10 mas.% saharoze.
The isolated antibody or antigen-binding fragment thereof of claim 1 or claim 2, wherein the antibody or fragment thereof competes for binding to LOXL2 with another antibody that specifically binds to a region of LOXL2 comprising SEQ ID NO: 6. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 1 ili zahtjevu 2, pri čemu protutijelo ili fragment obuhvaćaju varijabilni laki lanac s barem 75% aminokiselina identičnih aminokiselinskoj sekvenci u SEQ ID NO:2.
The process according to any one of claims 1-5, wherein the activating agent in step a2) is selected from a halogenating agent, C1-4alkyl acid halide, aryl acid halide, benzyl acid halide, C1-4alkyl haloformate, aryl haloformate, and benzyl haloformate. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što se aktivacijsko sredstvo u koraku a2) bira između halogenacijskog sredstva, halogenida C,yalkilne kiseline, izborno supstituiranog halogenida arilne kiseline, halogenida benzilne kiseline, C,,alkil-halogenformijata, izborno supstituiranog aril-halogenformijata i benzil-halogenformijata.
wherein the matrix comprises (i) at least one gum and (ii) at least one non-crystallising sugar or non-crystallising sugar alcohol. 
HR P20080289 T3 pri čemu matriks sadrži (i) najmanje jednu gumu i (ii) najmanje jedan ne-kristalizirajući šećer ili ne-kristalizirajući šećerni alkohol.
The solid oral extended release pharmaceutical dosage form of claim 1, wherein the active agent is oxycodone hydrochloride and wherein a dosage form comprising 10 mg of oxycodone hydrochloride when tested in a comparative clinical study is bioequivalent to a reference tablet containing 10 mg of oxycodone hydrochloride in a matrix formulation containing: Oxycodone hydrochloride: 10.0 mg/tablet Lactose (spray-dried): 69.25 mg/tablet 
Farmaceutski oblik doziranja s produljenim otpuštanjem u krutom obliku prema zahtjevu 1 ili 2, naznačen time da je aktivni agens oksikodon hidroklorid i pri čemu oblik za doziranje koji sadrži 10 mg oksikodon hidroklorida kada je testiran u komparativnoj kliničkoj studiji je bioekvivalentan referentnoj tableti koja sadrži 10 mg oksikodon hidroklorida u formulaciji matrice koja sadrži: a) Oksikodon hidroklorid: 10.0 mg/tableti b) Laktoza (suho raspršena): 69.25 mg/tableti 6) Povidon: 5,0 mg/tableti d) Eudragit" RS 30D (krutine); 10.0 mg/tableti
combinations thereof. The crystalline form of claim 1, wherein the crystalline form has an X-Ray powder diffraction (XRPD) pattern substantially the same as shown in Figure 1. 
Kristalni oblik prema bilo kojem od zahtjeva 1-3, naznačen time da navedeni kristalni oblik ima spektar difrakcije X-zraka praha (XRPD) isti kao što je prikazan na Slici 2.
Another aspect relates to a method of killing cancer cells in a subject, comprising the step of providing to the subject a therapeutically effective amount of the peptide of the invention, the nucleic acid of the invention, the cell of the invention, the immunoreactive cell of the invention, the binding agent of the invention, the T cell receptor of the invention, or the artificial T cell receptor of the invention. 
Peptid sukladno patentnom zahtjevu 1 ili 2, nukleinska kiselina sukladno patentnom zahtjevu 3 ili 12, stanica sukladno patentnom zahtjevu 4 i 13, T stanični receptor sukladno patentnom zahtjevu 5, ili stanični T receptor sukladno bilo kojem od patentnih zahtjeva 6 do 11, za uporabu u postupku uništavanja stanica raka kod subjekta, koji sadrži korak osiguranja terapeutski učinkovite količine peptida, nukleinske kiseline, stanice, T staničnog receptora ili umjetnog Tstaničnog receptora kod subjekta.
Use according to claims 1 to 4 wherein the composition is at least 50% protective, in a population of vaccinated individuals, against diarrhea and/or gastroenteritis and/or severe gastroenteritis caused by infection of a rotavirus of at least two non-G1 serotypes. 
Upotreba u skladu s patentnim zahtjevima 1 do 4, naznačena time što pripravak štiti najmanje 50% u populaciji osoba cijepljenih protiv proljeva i/ili gastroenteritisa i/ili jakog gastroenteritisa uzrokovanog infekcijom od strane najmanje dva serotipa rotavirusa koji nisu G1.
an IL-15 polypeptide, wherein the IL-15 polypeptide comprises at least one amino acid substitution at one or more positions corresponding to position(s) 92, 93, 94, 95, 96, 97, 98, 99, 100, 112, 113, 114, 115 and/or 116 of the amino acid sequence shown in SEQ ID NO:1 thereby having a reduced affinity for IL-15Ra compared to the affinity of wild-type IL-15 of SEQ ID NO: 1 (Uniprot number: P40933-1), wherein the IL-15 polypeptide binds to IL-2/IL-15RBY, wherein the binding protein is selected from the group consisting of an antibody, a divalent antibody fragment, a monovalent antibody fragment, or a proteinaceous binding molecule with antibody-like binding properties. 
polipeptid IL-15, gdje polipeptid IL-15 sadrži najmanje jednu aminokiselinsku zamjenu na jednom ili više položaja koji odgovaraju jednom ili više položaja 92, 93, 94, 95, 96, 97, 98, 99, 100, 112, 113, 114, 115 i/ili 116 u aminokiselinskom slijedu prikazanom u SEQ ID NO:1 pri čemu ima smanjeni afinitet za IL-15Ra u usporedbi s afinitetom divljeg tipa IL-15 sa SEQ ID NO: 1 (Uniprot broj: P40933-1), gdje se polipeptid IL-15 veže na IL-2/IL-15RBY, gdje se vežući protein bira iz skupine koju čine protutijelo, dvovalentni fragment protutijela, jednovalentni fragment protutijela ili proteinski vežuća molekula sa svojstvima vezanja kao kod protutijela.
19, pp 55) the surface of injury in all the aorta and the thickness of the intima in histological samples was determined. 
19, pp 55) utvrđena je površina ozljede u cijeloj aorti i debljina unutarnjeg dijela histoloških uzoraka.
a pipe (9) of a production or drilling line, said pipe (9) passing through the rotating stopper (54) and being arranged for containing and transporting extraction fluids such as, for example, petroleum, oil, water, sludge, rock debris and/or earth, natural gas, or other fluids extracted from the reservoir. 
cijev (9) proizvodne ili bušaće linije, gdje navedena cijev (9) prolazi kroz rotirajući zatvarač (54) 1 služi za držanje i transport ekstrakcijskih fluida, poput, primjerice, petroleja, nafte, vode, mulja, komadića stijena i/ili zemlje, zemnog plina, ili drugih fluida ekstrahiranih iz spremnika.